Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).

Autor: Kuitwaard K; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; Department of Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Fokkink WR; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Brusse E; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Vrancken AFJE; Department of Neurology, Brain Center Rudolf Magnus University Medical Center Utrecht, Utrecht, The Netherlands., Eftimov F; Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands., Notermans NC; Department of Neurology, Brain Center Rudolf Magnus University Medical Center Utrecht, Utrecht, The Netherlands., van der Kooi AJ; Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands., Merkies ISJ; Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.; Department of Neurology, St. Elisabeth Hospital, Willemstad, Curaçao., Jacobs BC; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., van Doorn PA; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of the peripheral nervous system : JPNS [J Peripher Nerv Syst] 2018 Mar; Vol. 23 (1), pp. 5-10. Date of Electronic Publication: 2017 Nov 21.
DOI: 10.1111/jns.12244
Abstrakt: High peak levels of serum IgG may not be needed for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with intravenous immunoglobulin (IVIg). More frequent dosing of IVIg leads to more stable IgG levels and higher trough levels which may be related with improved clinical efficacy. More frequent lower dosing leads to lower peak levels and may induce less systemic side-effects. The DRIP study is a double-blind randomized controlled cross-over intervention study. CIDP patients ≥18 years old, proven IVIg dependent and receiving an individually established but stable maintenance dose and interval of IVIg (Kiovig) can be included. One group (A) will be treated with their normal dosage and interval of IVIg and receive a placebo (albumin 0.5%) infusion in between their regular IVIg infusions, for a total of four infusions. The other group (B) will be treated with half their normal IVIg dosage (with the same volume of placebo to maintain the total volume) at half their interval (double their frequency) for four infusions. After a wash-out phase (2 infusions), patients will cross-over to the other treatment group. During the study the total dose of IVIg administered will remain unchanged as before start of the trial. The main objective is to investigate whether high frequent low dosage IVIg treatment is more effective than low frequent high dosage IVIg treatment as maintenance treatment for CIDP. Hand grip strength, as measured by the Martin Vigorimeter, will be used as the primary outcome measure. Secondary objective is to investigate whether high frequent low dosage of IVIg results in less adverse events compared to low frequent high dosage treatment. The DRIP study is currently ongoing and the protocol is presented.
(© 2017 Peripheral Nerve Society.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje